Slide 1: Cingulate Therapeutics
Cingulate Therapeutics Developing next-generation drug candidates where standard-of- care treatments result in suboptimal outcomes April 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than stat
Slide 3: Cingulate Mission
Cingulate Mission Cingulate will develop, shape market acceptance, and prepare to commercialize next- generation drug candidates in markets where currently prescribed standard-of-care treatments result in suboptimal outcomes for all stakeholders Achievement Drives Shareholder and Team Member Value v
Slide 4: Targeting Treatment of ADHD - $18Bn US Market Opportunity
Targeting Treatment of ADHD - $18Bn US Market Opportunity ~17 Million US ADHD Patients Adult ADHD Children & Adolescents + ~11M patients in the US and + ~6.4M patients in the US growing (65% of children with * 11.0% of the US under 18 net become Adults with population ) + ~80% receive treatment * 4.
Slide 5: $18 Billion US ADHD Market Dominated by Stimulants
$18 Billion US ADHD Market Dominated by Stimulants ulants 91% of US Market Y Despite multitude of options, patients’ needs are still not being met even by the most widely prescribed extended- Methylphenidates Amphetamines oe release ADHD medications = Ritalin®/LA = Vyvanse® * Concerta® * Adderall® /
Slide 6: ADHD Market Currently Dominated by Stimulant Products
ADHD Market Currently Dominated by 4 Stimulant Products dante ATTRIBUTES! MET NEEDS" Vyvanse® 2007 2 hours 12 hours 1% $11.68 Adderall® XR 2001 i 10 % hours 76% OMS Market Share ($)? Concerta® 2000 2 hours 10 hours \lo Focalin® XR 2005 30 mins 11% hours v ailable * Entire-active day efficacy defined
Slide 7: ADHD Market Leaders Do Not Provide “Built-In Booster”
ADHD Market Leaders Do Not Provide “Built-In Booster” eva ATTRIBUTES! RELEASE PROFILES’ 100% PRODRUG Vyvanse® 2 hours 12 hours SUSTAINED RELEASE 0 0 OVER 2- 3 HOURS Adderall® XR 4 yhours 10% hours --SO% IMMEDIATE RELEASE © 50% IMMEDIATE RELEASE AT HOUR 4 0 (and generics) Concerta® 78% SUSTAINED RELE
Slide 8: Recent Launches Lack Meaningful Clinical Innovation
Recent Launches Lack Meaningful Clinical Innovation ADHD BRANDS ATTRIBUTES" INMET NEEDS Quillivant / Chew® XR 60 mins 8 hours Mydayis® 2or4 hrs 16+ hours Potentially Adzenys® ER/ODT 60 mins 8-9 hours Cotempla® XR/ODT 60 mins 10-12 hours Aptensio® XR 60 mins 9 hours Evekeo® / ODT 60 mins 10 hours Dyn
Slide 9: The Cingulate Solution for ADHD Patients & Providers
The Cingulate Solution for ADHD Patients & Providers
Slide 10: Cingulate’s Precision Timed Release™ Platform Technology
Cingulate’s Precision Timed Release™ Platform Technology * Our current pipeline candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form, smaller than many single dose ADHD products * Each release is separated with a proprietary Erosion Barrier
Slide 11: Nine Significant Points of Differentiation
Nine Significant Points of Differentiation ADHD product available today PTR technology affords our product candidates the combines all unmet needs following potential advantages over currently available ADHD treatments Provide ‘entire active-day’ efficacy Reduce abuse / diversion by eliminating boos
Slide 12: CTx-1301 (d-MPH) and CTx-1302 (d-AMP)
CTx-1301 (d-MPH) and CTx-1302 (d-AMP) TARGET ATTRIBUTES RELEASE PROFILES CTx-1301 . Up to 16 45% SUSTAINED RELEASE OVER 90 20% IMMEDIATE (d-MPH) SOUS hours Sets MEST NEA SS MINUTES AT HOUR 3 RELEASE AT HOUR 7 CTx-1302 . Up to 16 35% SUSTAINED RELEASE OVER 90 20% IMMEDIATE (4-AMP) eit hours Goya DMMl
Slide 13: CTx-1301 Clinical Phase Study Results
CTx-1301 Clinical Phase 2 Study Results 3000 2500 2000 1500 1000 500 Plasma dexmethylphenidate (AMPH) Concentration vs Time Fast Onset Low Dose Extends duration for ‘entire active-day’ without the booster dose! Results demonstrate fast onset with the desired controlled descent Minimize ‘crash/reboun
Slide 14: At the Individual Level, Tri-modal Delivery is Clear
At the Individual Level, Tri-modal Delivery is Clear Entire Active-Day Efficacy, Stop the Crash & Rebound, Eliminate the Booster Dose Subject ID: 01-504 —® CTx-1301 6.25-mg —®— Focalin XR 5-mg —= CTx-1301 50-mg —® Focalin XR 40-mg 5 10 5 20 2s 30 “CINGULATE: Subject ID: 01-510 —® CTx-1301 6.25-mg —®
Slide 15: CTx-1301 Demonstrated Significantly Lower Adverse Events
CTx-1301 Demonstrated Significantly Lower Adverse Events Focalin XR CTx-1301 Focalin XR CTx-1301 All All 5 mg 6.25 mg 40 mg 50 mg CTx-1301 Focalin XR (n=41) (n=39) (n=43) (n=42) (n=42) (n=44) Treatment Emergent Adverse 7 (17.1%) 4 (10.3%) 22 (51.2%) 14 (33.3%) 17 (40.5%) 25 (56.8%) Events Mild 7 (17
Slide 16: Planned Phase Trials
MASTE RY Planned Phase 3 Trials 2019 - 2021 2022 2023 2024 Food Formulation Comparative Effect Study BA Study Study n=26 Pediatric / Pediatric Adolescent Efficacy & Fixed-Dose, Safety Placebo- Onset / Controlled Trial Duration n=300 n~50 Dose-Optimization Extension (6-17 y/o) Exploratory Endpoints i
Slide 17: Commercialization to Drive Revenue
Commercialization to Drive Revenue Changing dynamics in ADHD Maximize Access for Patients and Providers commercial landscape * — Efficacy, tolerability, 1 vs 2 Rx’s, Abuse/Diversion * — Ability to dominate share of voice + REBATES o Concerta, Adderall XR, Focalin XR are all + PBM's driven by rebate
Slide 18: Exclusivity: IP, Agreements, and Trade Secrets
Exclusivity: IP, Agreements, and Trade Secrets Intellectual property rights expected to provide exclusivity through 2035 at a minimum * — OralogiK™ Erosion Barrier Layer + Five (5) patents granted (US & Global) expiry dates ranging from 2031 to 2035, * One (1) Oralogik™ patent pending (US, Europe) *
Slide 19: Vast Pipeline of Next-Generation Medications Beyond ADHD
Vast Pipeline of Next-Generation Medications Beyond ADHD Y Leverage our PTR platform in other therapeutics areas VY Market Criteria: © $1Bn+ in peak sales © Next-generation mediations with significant improvement over existing therapies Identified PTR™ Platform Pipeline Opportunities Near-Term Focus
Slide 20: Cingulate Mission
Cingulate Mission Develop... Shape market acceptance, and... Prepare to commercialize next-generation drug candidates... Where currently prescribed standard-of-care treatments result in suboptimal outcomes for all stakeholders Achievement Drives Shareholder and Team Member Value
Slide 21: Appendix
“CINGULATE Appendix
Slide 22: Senior Management Team
Senior Management Team Leadership team brings extensive expertise in ADHD, clinical trials, pharmaceutical development, manufacturing, commercialization, market access, and patient care. Team has led 200+ clinical trials, 300+ publications, 30+ FDA drug approvals and the management of several billio
Slide 23: Board of Directors
Board of Directors Shane J Schaffer, PharmD Peter J Werth Chairman & Chief Executive Officer @Pfizer 1 NOVARTIS SANOFI x CHEMWERTH Jeff Conroy Gregg Givens ems. ost) py Josit pwe Patrick Gallagher, MBA CFA LAIDLAW COMPANY Jeff Hargroves Curt Medeiros, MBA ChemE i (>), PROPHARMA N ©) eet Yoptum: Oont
Slide 24: In-Vitro Comparison: CTx-1301 (25-mg) and Focalin XR (20-mg)
In-Vitro Comparison: CTx-1301 (25-mg) and Focalin XR (20-mg) CTx-1301 “Built-in Booster for Entire Active-Day” m= CTx-1301 Focalin XR “Done for the Day” == Focalin XR 3 Q 8 100 80 x 2 rr Ed g = a 2 3 i 3 8 2 $ z 2 g 3 vs 4-hour z 5 a Delay 2 « x 50 z ‘ 3 F $ Fd 2 a Immediate A Release o 2 4 6 8 20 a
Slide 25: CTx-1301 Clinical Phase Study Results
CTx-1301 Clinical Phase 2 Study Results PTR™ Technology Delivers Minimal Intersubject Variability ‘Actual Treatment = X= AsFocain XR tended Release cps mg Despite expected intersubject variability with all = So BCtetiortimdal 25m abit : : te methylphenidates, illustrated by the error bars, all the b
Slide 26: 100% of Stimulants Have Been Approved
100% of Stimulants Have Been Approved Methylphenidates Approval Date Azstarys* Adhansia XR* Jornay PM* Cotempla XR ODT* Quillichew ER* Quillivant XR* Aptensio XR* Daytrana* Focalin XR Methylin Chewable Tablets* Ritalin LA Focalin Metadate CD* Concerta Metadate ER* Desoxyn Ritalin 30 stimulant produc